Overview

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

Status:
WITHDRAWN

Trial end date:
2031-03-18

Target enrollment:

Participant gender:

Summary

Researchers want to learn if giving boserolimab (MK-5890) with standard treatment (pembrolizumab and chemotherapy) before surgery can help treat triple negative breast cancer (TNBC). The goals of this study are to learn about the safety of boserolimab given with standard treatment before surgery and to learn if people tolerate it and how many people have no signs of cancer in the tissues and lymph nodes removed during surgery.

Phase:

PHASE2

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

Capecitabine
Carboplatin
Cyclophosphamide
Doxorubicin
Epirubicin
olaparib
Paclitaxel
pembrolizumab